Firehawk®/TigerHawk® TARGET-FIRST Study Gains Global Recognition for Transforming DAPT Strategy in Low-Risk AMI Patients

Editor's Note:
On August 31, MicroPort^®Firehawk^®/Firehawk^®The European TARGET-FIRST clinical study results of the stent were simultaneously published on the dual top platforms of *The New England Journal of Medicine* and the European Society of Cardiology Congress (ESC 2025), demonstrating that: for the implantation of Firehawk^®/Firehawk^®For low-risk acute myocardial infarction patients who achieve complete revascularization with stents, reducing the dual antiplatelet therapy duration from 12 months to 1 month not only does not increase the risk of ischemia but also significantly decreases bleeding complications.

The release of this study has garnered significant attention and affirmation from the global medical community and media. Below are reports from some media outlets/academic institutions.